Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3814-3826

  Gill, Sumandeep K ^a   Xu, Hao ^a   Kirchhoff, Paul D ^a   Cierpicki, Tomasz ^b   Turbiak, Anjanette J ^a   Wan, Baojie ^c   Zhang, Nan ^c   Peng, Kuan Wei ^c   Franzblau, Scott G ^c   Garcia, George A ^a   Showalter, H D Hollis ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGNANE X RECEPTOR; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RNA POLYMERASE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; HUMAN; MICROSOME; MOLECULAR STABILITY; MOUSE; MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; DNA-DIRECTED RNA POLYMERASES; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; MICE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; RIFAMYCINS;

EID: 84860277072     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201716n     Document Type: Article

References (53)

1. WHO Report 2008. Global Tuberculosis Control: Surveillance, Planning, Financing; World Health Organization: Geneva, Switzerland, 2008.
2. Barrera, L. The Basics of Clinical Bacteriology. In Tuberculosis 2007: From Basic Science to Patient Care; Palomino, J. C., Leão, S. C., Ritacco, V., Eds.; Amedeo Challenge, 2007; pp 93-112.
3. Godreuil, S.; Tazi, L.; Bañuls, A.-L. Pulmonary Tuberculosis and Mycobacterium Tuberculosis: Modern Molecular Epidemiology and Perspectives. In Encyclopedia of Infectious Diseases: Modern Methodologies; Tibayrenc, M., Ed.; Wiley-Liss: Hoboken, NJ, 2007; pp 1-30.
4. Garcia, A. B.; Palacios, J. J.; Ruiz, M. J.; Barluenga, J.; Aznar, F.; Cabal, M. P.; Garcia, J. M.; Diaz, N. Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2010, 54 (12) 5363-5365
5. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis Nature 2011, 469 (7331) 483-490
6. Siddiqi, M. I.; Kumar, A. Review of knowledge for rational design and identification of anti-tubercular compounds Expert Opin. Drug Discovery 2009, 4 (10) 1005-1015
7. Lienhardt, C.; Vernon, A.; Raviglione, M. C. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Curr. Opin. Pulm. Med. 2010, 16 (3) 186-193
8. Aristoff, P. A.; Garcia, G. A.; Kirchhoff, P. D.; Showalter, H. D. H. Rifamycins: obstacles and opportunities Tuberculosis 2010, 90 (2) 94-118
9. Saito, H.; Tomioka, H.; Sato, K.; Emori, M.; Yamane, T.; Yamashita, K.; Hosoe, K.; Hidaka, T. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins Antimicrob. Agents Chemother. 1991, 35, 542-547
10. Lounis, N.; Roscigno, G. In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infection Curr. Pharm. Des. 2004, 10, 3229-3238 (Pubitemid 39276612)
11. Luna-Herrera, J.; Venkata Reddy, M.; Gangadharam, P. R. J. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli Antimicrob. Agents Chemother. 1996, 39, 440-444
12. Tomioka, H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities Curr. Pharm. Des. 2006, 12, 4047-4070 (Pubitemid 44669760)
13. Yamamoto, T.; Amitani, R.; Suzuki, K.; Tanaka, E.; Murayama, T.; Kuze, F. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1996, 40, 426-428 (Pubitemid 26053140)
14. Moghazeh, S.; Pan, X.; Arain, T.; Stover, C. K.; Musser, J. M.; Kreiswirth, B. N. Comparative antimycobacterial activities of rifampin, rifapentine and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations Antimicrob. Agents Chemother. 1996, 40, 2655-2657 (Pubitemid 26367663)
15. Yang, B.; Koga, H.; Ohno, H.; Ogawa, K.; Fukuda, M.; Hirakata, Y.; Maesaki, S.; Tomono, K.; Tashiro, T.; Kohno, S. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis J. Antimicrob. Chemother. 1998, 42, 621-628 (Pubitemid 28510620)
16. Mullin, S.; Rothstein, D. M.; Murphy, C. K. Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes Antimicrob. Agents Chemother. 2006, 50, 1908-1909
17. Roblin, P. M.; Reznik, T.; Kutlin, A.; Hammerschlag, M. R. In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae Antimicrob. Agents Chemother. 2003, 47, 1135-1136 (Pubitemid 36254248)
18. Brooks, J. V.; Orme, I. M. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model Antimicrob. Agents Chemother. 1998, 42, 3047-3048 (Pubitemid 28501254)
19. Klemens, S. P.; Grossi, M. A.; Cynamon, M. H. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model Antimicrob. Agents Chemother. 1994, 38, 2245-2248 (Pubitemid 24304211)
20. Kelly, B. P.; Furney, S. K.; Jessen, M. T.; Orme, I. M. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1996, 40, 2809-2812 (Pubitemid 26404349)
21. Klemens, S. P.; Cynamon, M. H. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model Antimicrob. Agents Chemother. 1996, 40, 298-301 (Pubitemid 26053136)
22. Lenaerts, A. M.; Chase, S. E.; Cynamon, M. H. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model Antimicrob. Agents Chemother. 2000, 44, 3167-3168
23. Shoen, C. M.; Chase, S. E.; DeStefano, M. S.; Harpster, T. S.; Chmielewski, A. J.; Cynamon, M. H. Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice Antimicrob. Agents Chemother. 2000, 44, 1458-1462 (Pubitemid 30340779)
24. Rifalazil. Tuberculosis (Edinburgh) 2008, 88, 148-150.
25. Mae, T.; Hosoe, K.; Yamamoto, T.; Hidaka, T.; Ohashi, T.; Kleeman, J. M.; Adams, P. E. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog Xenobiotica 1998, 28, 759-766 (Pubitemid 28399042)
26. Rose, L. M.; Porubek, D. J.; Montgomery, A. B. Method for Treatment of Bacterial Infections with Once- or Twice-Weekly Administered Rifalazil. WO2000035408A2, 2000.
27. Dietze, R.; Teixeira, L.; Rocha, L. M. C.; Palaci, M.; Johnson, J. L.; Wells, C.; Rose, L.; Eisenach, K.; Ellner, J. J. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis Antimicrob. Agents Chemother. 2001, 45, 1972-1976 (Pubitemid 32591685)
28. Rose, L. M.; Porubek, D. J.; Montgomery, A. B. Method for Treatment of Bacterial Infections with Once or Twice-Weekly Administered Rifalazil. US 6566354 B1, May 20, 2003.
29. Barry, P. J.; O'Connor, T. M. Novel agents in the management of Mycobacterium tuberculosis disease Curr. Med. Chem. 2007, 14 (18) 2000-2008 (Pubitemid 47209109)
30. Portero, J.-L.; Rubio, M. New anti-tuberculosis therapies Expert Opin. Ther. Pat. 2007, 17, 617-637 (Pubitemid 47045526)
31. Artsimovitch, I.; Vassylyeva, M. N.; Svetlov, D.; Svetlov, V.; Perederina, A.; Igarashi, N.; Matsugaki, N.; Wakatsuki, S.; Tahirov, T. H.; Vassylyev, D. G. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins Cell 2005, 122 (3) 351-63 (Pubitemid 41127138)
32. Sinz, M. W. Pregnane X receptor: prediction and attenuation of human CYP3A4 enzyme induction and drug-drug interactions Annu. Rep. Med. Chem. 2008, 43, 405-418
33. Chrencik, J. E.; Orans, J.; Moore, L. B.; Xue, Y.; Peng, L.; Collins, J. L.; Wisely, G. B.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin Mol. Endocrinol. 2005, 19 (5) 1125-1134 (Pubitemid 40594113)
34. Yamane, T.; Hashizume, T.; Yamashita, K.; Konishi, E.; Hosoe, K.; Hidaka, T.; Watanabe, K.; Kawaharada, H.; Yamamoto, T.; Kuze, F. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives Chem. Pharm. Bull. (Tokyo) 1993, 41 (1) 148-155 (Pubitemid 23071636)
35. Dhingra, K.; Maier, M. E.; Beyerlein, M.; Angelovski, G.; Logothetis, N. K. Synthesis and characterization of a smart contrast agent sensitive to calcium Chem. Commun. 2008, 29, 3444-3446 (Pubitemid 352009187)
36. Binggeli, A.; Christ, A. D.; Green, L.; Guba, W.; Maerki, H. P.; Martin, R. E.; Mohr, P. Preparation of Benzoxazole, Oxazolopyridine, Benzothiazole and Thiazolopyridine Derivatives as Somatostatin Receptor Modulators and Antidiabetic Compounds. WO2007025897A2, 2007.
37. Havera, H. J.; Strycker, W. G. 3-Substituted-5-phenyl-5- pyridylhydantoins. US3994904A, 1976.
38. Mae, T.; Konishi, E.; Hosoe, K.; Hidaka, T. Isolation and identification of major metabolites of rifalazil in mouse and human Xenobiotica 1999, 29, 1073-1087
39. Gill, S. K.; Garcia, G. A. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro Tuberculosis 2011, 91 (5) 361-369
40. Telenti, A.; Imboden, P.; Marchesi, F.; Lowrie, D.; Cole, S.; Colston, J.; Matter, L.; Schopfer, K.; Bodmer, T. Detection of rifampicin-resistance mutation in Mycobacterium tuberculosis Lancet 1993, 341, 647-650 (Pubitemid 23083244)
41. Williams, D. L.; Spring, L.; Collins, L.; Miller, L. P.; Heifets, L. B.; Gangadharam, P. R. J.; Gillis, T. P. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1998, 42, 1853-1857 (Pubitemid 28311593)
42. Collins, L.; Franzblau, S. Microplate Alamar Blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997, 41 (5) 1004-1009 (Pubitemid 27194176)
43. Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2007, 51 (4) 1380-1385 (Pubitemid 46586820)
44. Wang, J.; Huang, J.; Li, H.; Zhang, S. Synthesis of benzoxazinorifamycin derivatives and preliminary study of antibacterial activity Huaxi Yaoxue Zazhi 2003, 18 (4) 241-243
45. Labute, P. LowModeMD: implicit low mode velocity filtering applied to conformational search of macrocycles and protein loops J. Chem. Inf. Model. 2010, 50, 792-800
46. Molecular Operating Environment (MOE); Chemical Computing Group: Montreal, Canada, 2010.
47. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; Kliewer, S. A.; Redinbo, M. R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity Science 2001, 292 (5525) 2329-2333 (Pubitemid 32568055)
48. Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-Searles, P. R.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. 2.1 Å crystal structure of human PXR in complex with the St. John's wort compound hyperforin Biochemistry 2003, 42 (6) 1430-1438 (Pubitemid 36205949)
49. Teotico, D. G.; Bischof, J. J.; Peng, L.; Kliewer, S. A.; Redinbo, M. R. Structural basis of human pregnane X receptor activation by the hops constituent colupulone Mol. Pharmacol. 2008, 74 (6) 1512-1520
50. Jacques, J.-F.; Rodrigue, S.; Brzezinski, R.; Gaudreau, L. A recombinant Mycobacterium tuberculosis in vitro transcription system FEMS Microbiol. Lett. 2006, 255, 140-147
51. Jayaram, R.; Gaonkar, S.; Kaur, P.; Suresh, B. L.; Mahesh, B. N.; Jayashree, R.; Nandi, V.; Bharat, S.; Shandil, R. K.; Kantharaj, E.; Balasubramanian, V. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis Antimicrob. Agents Chemother. 2003, 47 (7) 2118-2124 (Pubitemid 36753560)
52. Jayaram, R.; Shandil, R. K.; Gaonkar, S.; Kaur, P.; Suresh, B. L.; Mahesh, B. N.; Jayashree, R.; Nandi, V.; Bharath, S.; Kantharaj, E.; Balasubramanian, V. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis Antimicrob. Agents Chemother. 2004, 48 (8) 2951-2957 (Pubitemid 38989160)
53. Shudo, J.; Pongpeerapat, A.; Wanawongthai, C.; Moribe, K.; Yamamoto, K. In vivo assessment of oral administration of probucol nanoparticles in rats Biol. Pharm. Bull. 2008, 31 (2) 321-325 (Pubitemid 351198412)